Keratoacanthoma: Rapid-Growing Skin Lesion – Diagnosis & Management
Keratoacanthoma (KA) is a common, rapidly growing, low-grade squamous cell carcinoma variant that often regresses spontaneously. It arises from hair follicle epithelium on sun-exposed skin.
Clinical Features
- Onset: Rapid growth over 2–6 weeks to 1–3 cm dome-shaped nodule
- Appearance: Symmetrical, flesh-colored to reddish, smooth surface with central keratin crater (horn plug)
- Location: Face, ears, scalp, forearms, dorsum of hands
- Demographics: Older adults (>60), fair skin, male predominance
- Symptoms: Often asymptomatic; may be tender, pruritic, or bleed
Differential Diagnosis
- Squamous cell carcinoma (SCC): Irregular borders, induration, fixation, slower growth, higher metastatic potential
- Basal cell carcinoma: Pearly telangiectatic papule, rolled borders, ulceration
- Seborrheic keratosis: Stuck-on, waxy, verrucous, no central crater
- Wart (verruca vulgaris): Rough, hyperkeratotic, multiple, viral etiology
Diagnosis
Biopsy (shave or punch) is required to distinguish KA from well-differentiated SCC. Histology: cup-shaped architecture with central keratin mass, glassy eosinophilic keratinocytes, minimal atypia, pushing margins. Clinical diagnosis alone is insufficient.
Treatment Options
| Method | Indication | Cure Rate | Notes |
|---|---|---|---|
| Surgical excision (4–5 mm margins) | Definitive treatment; all locations | 95–99% | Gold standard; allows full histologic assessment |
| Mohs micrographic surgery | High-risk sites (face, ears), recurrent, ill-defined | 97–99% | Tissue-sparing; real-time margin control |
| Curettage & electrodesiccation (C&E) | Small, low-risk trunk/extremities | 90–95% | Less cosmetic; no specimen for margins |
| Intralesional therapy | Non-surgical candidates, multiple lesions | Variable | 5-FU, methotrexate, bleomycin; limited evidence |
| Radiation therapy | Elderly, non-surgical, large lesions | 90%+ | Fractionated; long-term carcinogenesis risk |
| Observation | Classic KA in very elderly/frail; patient declines treatment | Spontaneous regression in ~50% over 2–6 months | Risk: progression to invasive SCC, scarring |
Follow-Up
- Skin exams every 6–12 months (increased risk of subsequent NMSC)
- Sun protection: broad-spectrum SPF 30+, protective clothing, avoidance of peak UV
- Consider nicotinamide 500 mg BID (ONTRAC trial: 23% reduction in new NMSC)
Keratoacanthoma behaves benignly in most cases, but definitive histologic diagnosis and treatment are standard of care to exclude invasive SCC and ensure optimal cosmetic outcome.
Tumors - Related Articles
- Psoriasis Treatment Options: From Topicals to Biologics and Lifestyle Adjuncts
- Understanding Spinal Tumor Progression: Rates & Types
- Neuroma: Understanding Causes, Types & Prognosis
- Sciatic Nerve Tumor: Causes, Symptoms & Treatment
- Diastema Treatment: Braces, Bonding, Veneers & More Options to Close Tooth Gaps
- Propolis: Bee‑Derived Resin with Emerging Anti‑Cancer and Immune‑Boosting Properties
- Thyroid Cancer Metastasis Treatments: Understanding Your Options
